Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006

JAMA

Volumn 302, Issue 19, 2009, Pages 2104-2110

  Kuklina, Elena V ^a   Yoon, Paula W ^a   Keenan, Nora L ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SCREENING; UNITED STATES;

ADULT; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREVALENCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 71749120653     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1672     Document Type: Article

References (26)

1. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med. 2006;6(5):571-587. (Pubitemid 44237154)
2. Grundy SM. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol. 2001;88(7B):23J-27J.
3. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208-1215.
4. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156(1):112-119.
5. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007;115(11):1363-1370.
6. Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J. 2005;150(3):595-601.
7. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263-269. (Pubitemid 41539788)
8. National Health and Nutrition Examination Survey data. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). http://www.cdc.gov/nchs/nhanes.htm. Accessed September 25, 2009.
9. Research ethics review board (ERB) approval. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). http://www.cdc.gov/nchs/nhanes/irba98.htm. Accessed September 25, 2009.
10. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary [October 16, 2008]. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp- iii.htm. Accessed October 19, 2009.
11. National Health and Nutrition Examination Survey Laboratory Protocol. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). Hyattsville, MD: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 1999-2006.
12. Cooper GR, Myers GL. Reference system for cholesterol measurements. Scand J Clin Lab Invest Suppl. 1990;198:27-31.
13. SUDAAN Example Manual. Research Triangle Park, NC: Research Triangle Institute; 2004.
14. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected US population. Healthy People 2010 Stat Notes. 2001;(20):1-10.
15. Clinical Policy Bulletin: screening for lipid disorders. Aetna. http://www.aetna.com/cpb/medical/data/500-599/0525.html. Accessed October 15, 2008.
16. Centers for Disease Control and Prevention (CDC). Disparities in screening for and awareness of high blood cholesterol: United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54(5):117-119.
17. Healthy people 2010, 2000. US Department of Health and Human Services. http://www.healthypeople.gov/. Accessed October 19, 2009.
18. Christian AH, Mills T, Simpson SL, Mosca L. Quality of cardiovascular disease preventive care and physician/practice characteristics. J Gen Intern Med. 2006;21(3):231-237.
19. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm. 2003;9(6):544-551.
20. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005;96(4A):53E-59E. (Pubitemid 41140371)
21. Sisson SD, Rice TN, Hughes MT. Physician knowledge of national cholesterol guidelines before and after an interactive curriculum. Am J Cardiol. 2007;99(9):1234-1235.
22. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13(8):652-663.
23. Ma Y, Li W, Olendzki BC, et al. Dietary quality 1 year after diagnosis of coronary heart disease. J Am Diet Assoc. 2008;108(2):240-246.
24. Hildemann S, Karmann B, Pittrow D, Barho C, Darius H, Bode C. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. Curr Med Res Opin. 2008;24(6):1659-1668. (Pubitemid 351929064)
25. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290(4):502-510. (Pubitemid 37430504)
26. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83(7):758-764.